- Home
- AVD vs ONCY Comparison
AVD vs ONCY Comparison
Compare AVD & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVD | ONCY |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 80.5M |
| IPO Year | 1995 | 2002 |
Fundamental Metrics
Financial Performance| Metric | AVD | ONCY |
|---|---|---|
| Price | $1.41 | $0.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.14 |
| AVG Volume (30 Days) | 300.5K | ★ 991.0K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $515,114,000.00 | N/A |
| Revenue This Year | $7.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.61 | $0.53 |
| 52 Week High | $5.53 | $1.32 |
Technical Indicators
Market Signals| Indicator | AVD | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 15.12 | 16.95 |
| Support Level | N/A | N/A |
| Resistance Level | $2.41 | $0.89 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 4.85 | 11.43 |
Price Performance
Historical ComparisonAbout AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. The company is a manufacturer of specialty solutions that develops and markets safe synthetic, biological, and biorational products for agricultural, commercial, and consumer uses. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.